GENPREX (GNPX) Competitors $0.29 +0.03 (+12.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.28 -0.01 (-3.33%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. ITRM, PYRGF, KLTO, MAAQ, RVPH, KZR, CASI, MIRA, DARE, and TENXShould you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include Iterum Therapeutics (ITRM), PyroGenesis Canada (PYRGF), Klotho Neurosciences (KLTO), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), MIRA Pharmaceuticals (MIRA), Dare Bioscience (DARE), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. GENPREX vs. Its Competitors Iterum Therapeutics PyroGenesis Canada Klotho Neurosciences Mana Capital Acquisition Reviva Pharmaceuticals Kezar Life Sciences CASI Pharmaceuticals MIRA Pharmaceuticals Dare Bioscience Tenax Therapeutics GENPREX (NASDAQ:GNPX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do analysts rate GNPX or ITRM? Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,218.68%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than GENPREX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENPREX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GNPX or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets GENPREXN/A -809.27% -386.95% Iterum Therapeutics N/A N/A -65.01% Which has more volatility & risk, GNPX or ITRM? GENPREX has a beta of -0.65, suggesting that its share price is 165% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500. Does the media refer more to GNPX or ITRM? In the previous week, GENPREX had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for GENPREX and 2 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 1.45 beat GENPREX's score of 0.50 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GENPREX Neutral Iterum Therapeutics Positive Do insiders & institutionals hold more shares of GNPX or ITRM? 14.1% of GENPREX shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 0.4% of GENPREX shares are held by insiders. Comparatively, 2.4% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, GNPX or ITRM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENPREXN/AN/A-$21.11MN/AN/AIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.80 SummaryIterum Therapeutics beats GENPREX on 8 of the 11 factors compared between the two stocks. Get GENPREX News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.76M$3.15B$5.79B$10.19BDividend YieldN/A2.32%5.73%4.60%P/E RatioN/A21.4375.4026.02Price / SalesN/A419.38514.85113.09Price / CashN/A44.4425.8129.91Price / Book1.949.6112.166.25Net Income-$21.11M-$53.29M$3.29B$270.76M7 Day Performance27.10%0.13%0.74%3.87%1 Month Performance35.05%5.55%5.00%5.49%1 Year Performance-30.55%10.44%62.55%25.86% GENPREX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGENPREX1.2351 of 5 stars$0.29+12.8%N/A-30.5%$9.76MN/A0.0020News CoverageShort Interest ↑ITRMIterum Therapeutics3.0031 of 5 stars$0.71+2.1%$9.00+1,169.6%-37.4%$32.75MN/A-0.8310Positive NewsShort Interest ↓PYRGFPyroGenesis CanadaN/A$0.17-0.7%N/A-67.9%$32.56M$9.14M-2.8990Gap UpHigh Trading VolumeKLTOKlotho Neurosciences0.4313 of 5 stars$0.62+19.1%N/AN/A$31.89MN/A-1.38N/AGap UpMAAQMana Capital AcquisitionN/A$3.76-4.9%N/A+1,200.6%$30.53MN/A0.001RVPHReviva Pharmaceuticals2.9856 of 5 stars$0.44-0.5%$5.20+1,073.5%-63.1%$30.29MN/A-0.685KZRKezar Life Sciences3.7561 of 5 stars$3.98-0.5%$9.00+126.1%-30.7%$29.29M$7M-0.4160News CoverageAnalyst UpgradeGap DownCASICASI Pharmaceuticals3.7778 of 5 stars$2.33-1.3%$4.00+71.7%-68.2%$29.02M$28.54M-0.81180MIRAMIRA Pharmaceuticals2.983 of 5 stars$1.66+9.2%$17.00+924.1%+7.4%$28.99MN/A-3.392News CoverageShort Interest ↓Gap UpHigh Trading VolumeDAREDare Bioscience2.3133 of 5 stars$2.11-0.9%$10.00+373.9%-36.3%$28.71M$10K-0.9930Short Interest ↓TENXTenax Therapeutics2.2603 of 5 stars$6.14+0.3%$18.00+193.2%+60.4%$27.92MN/A-6.679 Related Companies and Tools Related Companies ITRM Competitors PYRGF Competitors KLTO Competitors MAAQ Competitors RVPH Competitors KZR Competitors CASI Competitors MIRA Competitors DARE Competitors TENX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENPREX Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
